[1] |
LAU E, MOYERS J T, WANG B C, et al. Analysis of post-transplant lymphoproliferative disorder (PTLD) outcomes with Epstein-Barr virus (EBV) assessments-a single tertiary referral center experience and review of literature[J]. Cancers (Basel), 2021, 13(4): 899.
|
[2] |
SWERDLOW S H, CAMPO E, PILERI S A, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390.
doi: 10.1182/blood-2016-01-643569
|
[3] |
STYCZYNSKI J, VAN DER VELDEN W, FOX C P, et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: sixth European Conference on Infections in Leukemia (ECIL-6) guidelines[J]. Haematologica, 2016, 101(7): 803-811.
doi: 10.3324/haematol.2016.144428
|
[4] |
SCHIEFER A I, SALZER E, FÜREDER A, et al. PD-L1 and PD1 expression in post-transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: an inter- and intra-individual descriptive study covering the whole spectrum of PTLD categories[J]. Cancer Med, 2019, 8(10): 4656-4668.
doi: 10.1002/cam4.2394
|
[5] |
PETRARA M R, GIUNCO S, SERRAINO D, et al. Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment[J]. Cancer Lett, 2015, 369(1): 37-44.
doi: 10.1016/j.canlet.2015.08.007
|
[6] |
OPELZ G, HENDERSON R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients[J]. Lancet, 1993, 342(8886/8887): 1514-1516.
doi: 10.1016/S0140-6736(05)80084-4
|
[7] |
COCKFIELD S M. Identifying the patient at risk for post-transplant lymphoproliferative disorder[J]. Transpl Infect Dis, 2001, 3(2): 70-78.
doi: 10.1034/j.1399-3062.2001.003002070.x
|
[8] |
OPELZ G, DÖHLER B. Lymphomas after solid organ transplantation: a collaborative transplant study report[J]. Am J Transplant, 2004, 4(2): 222-230.
doi: 10.1046/j.1600-6143.2003.00325.x
|
[9] |
WISTINGHAUSEN B, GROSS T G, BOLLARD C. Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients[J]. Pediatr Hematol Oncol, 2013, 30(6): 520-531.
doi: 10.3109/08880018.2013.798844
|
[10] |
UHLIN M, WIKELL H, SUNDIN M, et al. Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation[J]. Haematologica, 2014, 99(2): 346-352.
doi: 10.3324/haematol.2013.087338
|
[11] |
NAKANISHI C, KAWAGISHI N, SEKIGUCHI S, et al. Post-transplantation lymphoproliferative disorder in living-donor liver transplantation: a single-center experience[J]. Surg Today, 2012, 42(8): 741-751.
doi: 10.1007/s00595-012-0127-7
|
[12] |
STYCZYNSKI J, GIL L, TRIDELLO G, et al. Response to rituximab-based therapy and risk factor analysis in Epstein Barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the infectious diseases working party of the European group for blood and marrow transplantation[J]. Clin Infect Dis, 2013, 57(6): 794-802.
doi: 10.1093/cid/cit391
|
[13] |
DIERICKX D, HABERMANN T M. Post-transplantation lymphoproliferative disorders in adults[J]. N Engl J Med, 2018, 378(6): 549-562.
doi: 10.1056/NEJMra1702693
|
[14] |
LUSKIN M R, HEIL D S, TAN K S, et al. The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder[J]. Am J Transplant, 2015, 15(10): 2665-2673.
doi: 10.1111/ajt.13324
|
[15] |
DESTEFANO C B, DESAI S H, SHENOY A G, et al. Management of post-transplant lymphoproliferative disorders[J]. Br J Haematol, 2018, 182(3): 330-343.
doi: 10.1111/bjh.15263
|
[16] |
MALONEY E M, BUSQUE V A, HUI S T, et al. Genomic variations in EBNA3C of EBV associate with posttransplant lymphoproliferative disorder[J]. JCI Insight, 2020, 5(6): 131644.
|
[17] |
GULLEY M L, TANG W H. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder[J]. Clin Microbiol Rev, 2010, 23(2): 350-366.
doi: 10.1128/CMR.00006-09
|
[18] |
中华医学会器官移植学分会. 器官移植受者EB病毒感染和移植后淋巴组织增生性疾病临床诊疗规范(2019版)[J]. 器官移植, 2019, 10(2): 149-157.
|
|
Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specification for EB virus infection and posttransplant lymphoproliferative disease on recipients with organ transplantation in China (2019 edition)[J]. Organ Transplant, 2019, 10(2): 149-157.
|
[19] |
KANAKRY J A, HEGDE A M, DURAND C M, et al. The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases[J]. Blood, 2016, 127(16): 2007-2017.
doi: 10.1182/blood-2015-09-672030
|
[20] |
KIMURA H, KWONG Y L. EBV viral loads in diagnosis, monitoring, and response assessment[J]. Front Oncol, 2019, 9: 62.
doi: 10.3389/fonc.2019.00062
|
[21] |
ALLEN U D, PREIKSAITIS J K, AST INFECTIOUS DISEASES COMMUNITY OF PRACTICE. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation[J]. Am J Transplant, 2013, 13(Suppl 4): 107-120.
doi: 10.1111/ajt.12104
|
[22] |
CAMPO E, SWERDLOW S H, HARRIS N L, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications[J]. Blood, 2011, 117(19): 5019-5032.
doi: 10.1182/blood-2011-01-293050
|
[23] |
RAUSCH L, KOENECKE C, KOCH H F, et al. Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation[J]. Transplant Res, 2016, 5: 6.
doi: 10.1186/s13737-016-0036-1
|
[24] |
刘彦权, 沈建箴, 刘庭波, 等. 第504例孕32周、贫血—顽固性溶血性贫血—重症肺部感染—心功能不全—左肾占位—弥漫大B细胞淋巴瘤[J]. 中华医学杂志, 2020, 100(20): 1588-1592.
|
|
LIU Y Q, SHEN J Z, LIU T B, et al. Case 504, 32 weeks of gestation, anemia-refractory hemolytic anemia-severe pulmonary infection-cardiac dysfunction-left renal mass-diffuse large B-cell lymphoma[J]. Natl Med J China, 2020, 100(20): 1588-1592.
|
[25] |
READY E, CHERNUSHKIN K, PARTOVI N, et al. Posttransplant lymphoproliferative disorder in adults receiving kidney transplantation in British Columbia: a retrospective cohort analysis[J]. Can J Kidney Health Dis, 2018, 5: 2054358118760831.
|
[26] |
TAOKA K, NANNYA Y, YAMAMOTO G, et al. Progressive transition of Epstein-Barr virus associated lymphoproliferative disease subtypes with the development of lung cancer[J]. Am J Hematol, 2009, 84(9): 600-603.
doi: 10.1002/ajh.21479
|
[27] |
AFSHAR K, RAO A P, PATEL V, et al. Use of foscarnet therapy for EBV infection following control of PTLD with enhancement of cellular immunity in a lung-transplant recipient[J]. J Transplant, 2011, 2011: 919651.
|
[28] |
HÖCKER B, BÖHM S, FICKENSCHER H, et al. (Val-) Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation[J]. Transpl Int, 2012, 25(7): 723-731.
doi: 10.1111/j.1432-2277.2012.01485.x
|
[29] |
PETERS A C, AKINWUMI M S, CERVERA C, et al. The changing epidemiology of posttransplant lymphoproliferative disorder in adult solid organ transplant recipients over 30 years: a single-center experience[J]. Transplantation, 2018, 102(9): 1553-1562.
doi: 10.1097/TP.0000000000002146
|
[30] |
PARKER A, BOWLES K, BRADLEY J A, et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients-BCSH and BTS guidelines[J]. Br J Haematol, 2010, 149(5): 693-705.
doi: 10.1111/j.1365-2141.2010.08160.x
|
[31] |
TSAI D E, HARDY C L, TOMASZEWSKI J E, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients[J]. Transplantation, 2001, 71(8): 1076-1088.
doi: 10.1097/00007890-200104270-00012
|
[32] |
GHOBRIAL I M, HABERMANN T M, RISTOW K M, et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era[J]. Leuk Lymphoma, 2005, 46(2): 191-196.
doi: 10.1080/10428190400012011
|
[33] |
CHOQUET S, LEBLOND V, HERBRECHT R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study[J]. Blood, 2006, 107(8): 3053-3057.
doi: 10.1182/blood-2005-01-0377
|
[34] |
BISHNOI R, BAJWA R, FRANKE A J, et al. Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients[J]. Exp Hematol Oncol, 2017, 6: 26.
doi: 10.1186/s40164-017-0087-0
|
[35] |
TRAPPE R U, DIERICKX D, ZIMMERMANN H, et al. Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase Ⅱ trial[J]. J Clin Oncol, 2017, 35(5): 536-543.
|
[36] |
TRAPPE R, OERTEL S, LEBLOND V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial[J]. Lancet Oncol, 2012, 13(2): 196-206.
doi: 10.1016/S1470-2045(11)70300-X
|
[37] |
MYNAREK M, SCHOBER T, BEHRENDS U, et al. Posttransplant lymphoproliferative disease after pediatric solid organ transplantation[J]. Clin Dev Immunol, 2013, 2013: 814973.
|
[38] |
GROSS T G, ORJUELA M A, PERKINS S L, et al. Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a children’s oncology group report[J]. Am J Transplant, 2012, 12(11): 3069-3075.
doi: 10.1111/j.1600-6143.2012.04206.x
|